Floatz logo

SIMVASTATIN

Peripheral Arterial Disease

University of OxfordSmall moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Peripheral Arterial Disease cohort.

Asset / SponsorPhaseRating
Plavix
Shanghai CureGene Pharmaceutical Co., Ltd.
Phase 4BBB
Acetylsalicylic Acid
Shanghai CureGene Pharmaceutical Co., Ltd.
Phase 4BBB
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
University of Ioannina
Phase 4BB
Ranolazine
Colorado Prevention Center
Phase 4BB
Ticagrelor
AstraZeneca
Phase 3BB

View all 14 →

Same molecule, other indications

SIMVASTATIN is also rated in:

HypercholesterolemiaDormant
BBB
Indicative ·
76 / 100
View asset →
psychotic disorderDormant
BBB
Indicative ·
75 / 100
View asset →
inherited lipid metabolism disorderDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →